Conatus Pharmaceuticals' IDN-7314 was granted orphan drug designation by the European Medicines Agency as a treatment for patients with primary sclerosing cholangitis. The drug, an orally available pan-caspase protease inhibitor, also received orphan drug designation from the FDA in June.
EMA grants orphan status to Conatus' PSC drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.